Clinical significance of lymph node ratio in locally advanced breast cancer molecular subtypes

Erişim
info:eu-repo/semantics/closedAccessTarih
2013
11 readers on Mendeley
Üst veri
Tüm öğe kaydını gösterKünye
Demircioglu, F., Demirci, U., Kilic, D., Ozkan, S., Karahacioglu, F. (2013). Clinical significance of lymph node ratio in locally advanced breast cancer molecular subtypes. Onkologie, 36(11), 637-640. https://doi.org/10.1159/000355663Özet
Background: the ratio of metastatic to dissected lymph nodes (lymph node ratio; LNR) is a sensitive and superior prognostic factor for lymph node evaluation, but its relationship to cancer subtypes is unclear. Patients and Methods: Data from 469 patients with axillary lymph node metastasis out of 640 early breast cancer cases were retrospectively analyzed. They were classified into 4 molecular subtypes; lumina! A, luminal B HER2(+), HER2 overexpression, basal-like. LNRs were compared between groups and with other prognostic factors. Results: the distribution of LNRs was 35.2% in luminal A, 43.2% in luminal B HER2(+), 46.9% in HER2 overexpression, and 39.1% in basal-like. A significant difference was found between lumina! A and HER2 overexpression subtypes (p = 0.023). LNR was significantly correlated with tumor size and lymphovascular invasion, but not with other prognostic factors including menopausal status, laterality, grade, and perineural invasion. An LNR of 29.8% was defined as the cut-off value, and significant differences in survival rates were identified accordingly between basal-like and both luminal A (p = 0.003) and luminal B HER2(+) (p = 0.04). Conclusion: the LNR differs between some molecular subtypes of breast cancer, and it correlates with certain prognostic factors and survival. These data support using the LNR to assess breast cancer patients.